Demographic and clinical characteristics
| 25–28 Weeks | 29–32 Weeks | |||
|---|---|---|---|---|
| MIST (n=38) | Controls (n=41) | MIST (n=23) | Controls (n=56) | |
| Study site | RHH 19; RWH 19 | RHH 16; RWH 25 | RHH 12; RWH 11 | RHH 20; RWH 36 |
| Gestation (weeks) | 27 (26–28) | 27 (26–27) | 30 (29–31) | 31 (30–31) |
| Birth weight (grams) | 880 (770–1030) | 960 (820–1128) | 1670 (1490–1790) | 1505 (1340–1715) |
| Male gender | 17 (45%) | 24 (59%) | 12 (52%) | 30 (54%) |
| Singleton | 28 (74%) | 24 (59%) | 18 (78%) | 26 (46%) |
| Antenatal corticosteroids (any) | 35 (92%) | 38 (93%) | 15 (65%) | 46 (82%) |
| Caesarean delivery | 30 (79%) | 27 (66%) | 20 (87%) | 46 (82%) |
| 5 Min Apgar score | 8 (7–9) | 8 (7–9) | 9 (7.5–9) | 8.5 (8–9) |
Median (IQR) or n (%).
Controls, infants managed on continuous positive airway pressure prior to the feasibility study and achieving the same FiO2 thresholds; MIST, infants receiving minimally-invasive surfactant therapy; RHH, Royal Hobart Hospital; RWH, Royal Women's Hospital, Melbourne.